Duloxetine + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis
Conditions
Osteoarthritis
Trial Timeline
Sep 1, 2013 → Jun 1, 2015
NCT ID
NCT01931475About Duloxetine + Placebo
Duloxetine + Placebo is a phase 3 stage product being developed by Eli Lilly for Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01931475. Target conditions include Osteoarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01931475 | Phase 3 | Completed |
| NCT01451606 | Approved | Terminated |
| NCT01226511 | Phase 3 | Completed |
| NCT01179672 | Phase 3 | Completed |
| NCT01237587 | Phase 3 | Completed |
| NCT01118780 | Approved | Completed |
| NCT01070329 | Approved | Completed |
| NCT01000805 | Approved | Completed |
| NCT01018680 | Phase 3 | Completed |
| NCT00965081 | Approved | Completed |
| NCT00803361 | Phase 3 | Completed |
| NCT00767806 | Phase 3 | Completed |
| NCT00433290 | Phase 3 | Completed |
| NCT00424593 | Phase 3 | Completed |
| NCT00457730 | Phase 2/3 | Completed |
| NCT00408876 | Phase 3 | Completed |
| NCT00408421 | Phase 3 | Completed |
| NCT00607789 | Approved | Completed |
| NCT00375973 | Phase 2/3 | Completed |
| NCT00233025 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoarthritis